Cargando…

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients

Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Campione, Elena, Lambiase, Sara, Gaeta Shumak, Ruslana, Galluzzo, Marco, Lanna, Caterina, Costanza, Gaetana, Borselli, Cristiana, Artosi, Fabio, Cosio, Terenzio, Tofani, Lorenzo, Dattola, Annunziata, Di Daniele, Francesca, Bianchi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141711/
https://www.ncbi.nlm.nih.gov/pubmed/37111283
http://dx.doi.org/10.3390/ph16040526
_version_ 1785033444309336064
author Campione, Elena
Lambiase, Sara
Gaeta Shumak, Ruslana
Galluzzo, Marco
Lanna, Caterina
Costanza, Gaetana
Borselli, Cristiana
Artosi, Fabio
Cosio, Terenzio
Tofani, Lorenzo
Dattola, Annunziata
Di Daniele, Francesca
Bianchi, Luca
author_facet Campione, Elena
Lambiase, Sara
Gaeta Shumak, Ruslana
Galluzzo, Marco
Lanna, Caterina
Costanza, Gaetana
Borselli, Cristiana
Artosi, Fabio
Cosio, Terenzio
Tofani, Lorenzo
Dattola, Annunziata
Di Daniele, Francesca
Bianchi, Luca
author_sort Campione, Elena
collection PubMed
description Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaque-type psoriasis in adults based on the evidence of two randomized and controlled phase-III clinical trials (reSURFACE 1 and reSURFACE 2). Here, we report our real-life experience treating 53 psoriatic patients (19 female and 34 male) who were administered tildrakizumab every 12 weeks and received follow-ups over 52 weeks. Descriptive and inferential statistical analyses were performed, in particular the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and, if applicable, the Nail Psoriasis Severity Index (NAPSI) and Palmoplantar Psoriasis Physician Global Assessment (PPPGA). These were assessed at baseline and after different timepoints (weeks) during the follow-up period. We described and evaluated demographical and epidemiological characteristics in our cohort group, focusing on comorbidities. In this group, 35.9% of patients were female and 64.1% were male, with 47.1% being smokers and with a mean age of 51.2 years. A total of 37.7% of these patients was affected by scalp psoriasis; regarding comorbidities, hypertension was the most frequent (32.5%), followed by psoriatic arthritis (PsA) (18.60%) and diabetes (13.9%). At week 52, 93%, 90.2% and 77% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. In addition, NAPSI, PPPGA and DLQI scores were significantly reduced by week 52. In our cohort of complex psoriasis patients, disease remission began at the end of the fourth week of treatment and remained constant from week 16 to week 52.
format Online
Article
Text
id pubmed-10141711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101417112023-04-29 A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients Campione, Elena Lambiase, Sara Gaeta Shumak, Ruslana Galluzzo, Marco Lanna, Caterina Costanza, Gaetana Borselli, Cristiana Artosi, Fabio Cosio, Terenzio Tofani, Lorenzo Dattola, Annunziata Di Daniele, Francesca Bianchi, Luca Pharmaceuticals (Basel) Article Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaque-type psoriasis in adults based on the evidence of two randomized and controlled phase-III clinical trials (reSURFACE 1 and reSURFACE 2). Here, we report our real-life experience treating 53 psoriatic patients (19 female and 34 male) who were administered tildrakizumab every 12 weeks and received follow-ups over 52 weeks. Descriptive and inferential statistical analyses were performed, in particular the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and, if applicable, the Nail Psoriasis Severity Index (NAPSI) and Palmoplantar Psoriasis Physician Global Assessment (PPPGA). These were assessed at baseline and after different timepoints (weeks) during the follow-up period. We described and evaluated demographical and epidemiological characteristics in our cohort group, focusing on comorbidities. In this group, 35.9% of patients were female and 64.1% were male, with 47.1% being smokers and with a mean age of 51.2 years. A total of 37.7% of these patients was affected by scalp psoriasis; regarding comorbidities, hypertension was the most frequent (32.5%), followed by psoriatic arthritis (PsA) (18.60%) and diabetes (13.9%). At week 52, 93%, 90.2% and 77% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. In addition, NAPSI, PPPGA and DLQI scores were significantly reduced by week 52. In our cohort of complex psoriasis patients, disease remission began at the end of the fourth week of treatment and remained constant from week 16 to week 52. MDPI 2023-03-31 /pmc/articles/PMC10141711/ /pubmed/37111283 http://dx.doi.org/10.3390/ph16040526 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Campione, Elena
Lambiase, Sara
Gaeta Shumak, Ruslana
Galluzzo, Marco
Lanna, Caterina
Costanza, Gaetana
Borselli, Cristiana
Artosi, Fabio
Cosio, Terenzio
Tofani, Lorenzo
Dattola, Annunziata
Di Daniele, Francesca
Bianchi, Luca
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
title A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
title_full A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
title_fullStr A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
title_full_unstemmed A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
title_short A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
title_sort real-life study on the use of tildrakizumab in psoriatic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141711/
https://www.ncbi.nlm.nih.gov/pubmed/37111283
http://dx.doi.org/10.3390/ph16040526
work_keys_str_mv AT campioneelena areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT lambiasesara areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT gaetashumakruslana areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT galluzzomarco areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT lannacaterina areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT costanzagaetana areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT borsellicristiana areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT artosifabio areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT cosioterenzio areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT tofanilorenzo areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT dattolaannunziata areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT didanielefrancesca areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT bianchiluca areallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT campioneelena reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT lambiasesara reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT gaetashumakruslana reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT galluzzomarco reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT lannacaterina reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT costanzagaetana reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT borsellicristiana reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT artosifabio reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT cosioterenzio reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT tofanilorenzo reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT dattolaannunziata reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT didanielefrancesca reallifestudyontheuseoftildrakizumabinpsoriaticpatients
AT bianchiluca reallifestudyontheuseoftildrakizumabinpsoriaticpatients